Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6750156 | 1.00 | KDM4E (0.37) | KDM4EPKMSPHK1BRD4HSD11B2 | |
| SCHEMBL6232927 | 0.87 | CYP2D6 (0.33) | — | |
| SCHEMBL6746218 | 0.87 | CYP2D6 (0.33) | — | |
| SCHEMBL4595234 | 0.87 | CYP2D6 (0.33) | — | |
| SCHEMBL6746223 | 0.87 | CYP2D6 (0.33) | — | |
| SCHEMBL16160965 | 0.86 | BRD4 (0.34) | KDM4EPKMSPHK1BRD4HSD11B2 | |
| SCHEMBL6186128 | 0.83 | CYP2D6 (0.42) | KDM4EPKMSPHK1BRD4HSD11B2 | |
| SCHEMBL6186125 | 0.83 | CYP2D6 (0.42) | KDM4EPKMSPHK1BRD4HSD11B2 | |
| SCHEMBL6752549 | 0.78 | ITGB3 (0.37) | KDM4E | |
| SCHEMBL6748055 | 0.77 | CYP2D6 (0.39) | SPHK1BRD4HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | CYP1A1, NOS3, NOS1 | KDM4E 2387/4885PKM 2306/4885SPHK1 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.